25
Tue, Apr
9 New Articles

Bayer HealthCare announced that researchers have presented data from two international long-term follow-up studies in multiple sclerosis: the BENEFIT (BEtaferon in Newly Emerging multiple sclerosis For Initial Treatment) 8-Year Extension Study and the Betaferon® 21-Year Long-term Follow-up (LTF) Study. The abstracts were presented at the Fifth Triennial Meeting of the European and American Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS - ACTRIMS) in Amsterdam, The Netherlands.

Shire plc, the global specialty biopharmaceutical company, today presented positive top line results of the first European phase III study of once-daily lisdexamfetamine dimesylate (LDX) in children and adolescents aged 6 to 17 years with Attention-Deficit/Hyperactivity Disorder (ADHD)1.  LDX is the first chemically formulated long-acting, prodrug of dexamfetamine for treatment of ADHD, and is currently licensed only in the US, Canada and Brazil.

Eli Lilly and Company announced that a pivotal Phase III study of Cialis® (tadalafil) tablets 5 mg for once daily use met its co-primary endpoints, significantly improving measures of both erectile dysfunction (ED) and signs and symptoms of benign prostatic hyperplasia (BPH) in men with both conditions. The study is available online in The Journal of Sexual Medicine. It is one of three efficacy and safety studies included in the supplemental new drug application Lilly submitted to the U.S. Food and Drug Administration (FDA) last year seeking approval for Cialis in the treatment of the signs and symptoms of BPH and the treatment of both ED and the signs and symptoms of BPH (ED+BPH).

Eli Lilly and Company announced that PARAMOUNT, its Phase III study evaluating ALIMTA® (pemetrexed for injection) in the continuation maintenance setting, met its primary endpoint of progression-free survival, or the time a patient is alive without their disease worsening, for patients with a specific type of lung cancer called advanced nonsquamous non-small cell lung cancer (NSCLC).

Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext in Paris, with a focus on research and development of new treatments of proliferative diseases, announces today the online publication of a scientific article by Dr Ryoko Okamoto and co-authors in the peer-reviewed International Journal of Cancer*. Their preclinical results demonstrate the potential of inecalcitol to inhibit the proliferation of human cancer cells in vitro, as well as the growth of hormone-dependent prostate cancer xenografts in vivo in mice. Dr Okamoto works in Prof Phillip Koeffler's Division of Hematology and Oncology at the Cedars-Sinai Medical Center of the UCLA School of Medicine.

A study co-led by researchers at King’s College London shows that the percentage of men who had a radical prostatectomy (removal of the prostate and surrounding cancer cells) and survived for 15 years is higher than men who were only given treatment at signs of further progression of prostate cancer,  an approach known as ‘watchful waiting.

More Articles ...